Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis Registry

Loriane Marina Michèle Verleye(Maastricht University Medical Centre), Tessa Straatmijer(Leiden University Medical Center), Martine van Workum, Zlatan Mujagic(Maastricht University Medical Centre), Myrthe R Naber(University Medical Center Utrecht), Nynke Boontje, Vince Biemans(Radboud University Nijmegen), Philip W. Voorneveld(Leiden University Medical Center), Steven Jeuring, Willemijn A. van Dop(Leiden University Medical Center), Loes H.C. Nissen(Radboud University Nijmegen), Bindia Jharap(Meander Medisch Centrum), Malena Schlotter, Marjolijn Duijvestein(Amsterdam University Medical Centers), Mark Lowenberg(Amsterdam Neuroscience), Marthe H. Verwey, Rachel West(Sint Franciscus Gasthuis), Herma H. Fidder(University Medical Center Utrecht), T. Römkens(Jeroen Bosch Ziekenhuis), Fiona D.M. van Schaik(University Medical Center Utrecht), Marijn C Visschedijk(University Medical Center Groningen), Alexander GL Bodelier(Amphia Ziekenhuis), Bas Oldenburg(University Medical Center Utrecht), Marieke J Pierik(Maastricht University Medical Centre), Dianne G; id_orcid 0000-0002-6208-2967 Bouwknegt(University Medical Center Groningen), Annemarie C de Vries(Erasmus MC), Lauranne AAP Derikx(Erasmus MC), Andrea E van der Meulen - de Jong(Leiden University Medical Center), Miranda Bouwens, Ilse Sour, Safioen Nabibaks, the Dutch Initiative on Crohn and Colitis (ICC), Anne Meyboom, Sandra Cosijns, Kyra Hermans, Ingrid Willemen-Boemaars, Jael Smid
Inflammatory Bowel Diseases
February 27, 2026
Cited by 0


Related Papers